Essential phospholipids and enzyme-based staging in nonalcoholic fatty liver disease: A call to action

doi:10.4254/wjh.v17.i11.110725

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (112)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=63

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=34

Nov 27, 2025 (publication date) through Dec 4, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Nov 27, 2025; 17(11): 110725
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110725

Essential phospholipids and enzyme-based staging in nonalcoholic fatty liver disease: A call to action

Ali Madian

Ali Madian, Department of Internal Medicine, Faculty of Medicine, Al-Azhar University-Assiut, Assiut 71524, Egypt

Author contributions: Madian A conceptualized the editorial, drafted the manuscript, reviewed and revised the content, and approved the final version for submission.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Ali Madian, MD, PhD, Associate Professor, Consultant, Department of Internal Medicine, Faculty of Medicine, Al-Azhar University-Assiut, Al Walideyah Al Bahreyah, Assiut 71524, Egypt. a.madian@azhar.edu.eg

Received: June 13, 2025
Revised: July 8, 2025
Accepted: September 2, 2025
Published online: November 27, 2025
Processing time: 167 Days and 18.1 Hours

Core Tip

Core Tip: The MANPOWER study demonstrated that Essentiale Forte N^® reduces liver enzyme levels (alanine aminotransferase: 20-37 U/L, aspartate aminotransferase: 17-29 U/L, gamma-glutamyl transferase: 17-24 U/L, P < 0.001) and improves ultrasonography findings in patients with nonalcoholic fatty liver disease, with greater efficacy in severe cases. A liver enzyme-based algorithm offers 72.3% accuracy for noninvasive staging, prompting clinicians to adopt essential phospholipids and researchers to refine scalable diagnostics to address nonalcoholic fatty liver disease’s global burden.